Ann: Immutep Investor Update, page-2

"
2019 promises to be a very data heavy year
for Immutep, with multiple value enhancing clinical data sets expected.
During 2019 we are on track to report:
• first clinical data from our Phase IIb AIPAC study (primary PFS read out)
• final data from our Phase I TACTI-mel study
• first data from our Phase II TACTI-002 study
• first data from the Phase I IKF INSIGHT-004 study (Pfizer Inc., Merck KGaA)
• data from the in vivo study with IMP761"

An excellent update with so much potential here. Investors will wake up this little gem soon....2019 will be our year. Glta.